Investors & Media

Aug 13, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Aug 13, 2020 / Aug 13, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

8/13/20

BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights
- Phase 2b Trial Design for BLU-5937 in Refractory Chronic Cough to be Announced in Q3 2020 - LAVAL, Quebec --(BUSINESS WIRE)--Aug. 13, 2020-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Read More
7/6/20

BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
- Primary endpoint of placebo-adjusted reduction in awake cough frequency did not reach statistical significance - - Highly statistically significant and clinically meaningful reductions in placebo adjusted awake cough frequency achieved in pre-specified analysis of high cough count patients...
Read More
5/28/20

BELLUS Health to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
LAVAL, Quebec --(BUSINESS WIRE)--May 28, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More